BioSpace News Archive

Experts Introduce 71 Abstracts at the American Society of Nephrology’s 2018 Kidney Week Symposium, The World’s Largest Gathering of Kidney Professionals

Henry Schein, Inc. announced today that it will release its third quarter 2018 financial results before the stock market opens on Tuesday, November 6, 2018, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

Pioneer Physicians Network, a leading primary care independent physician group in Northeast Ohio, today announced the launch of Paradigm Senior Care Advantage, an innovative new model designed to deliver high-quality, affordable care to an estimated 10,000 seniors in Northeast Ohio in 2019.

Eight internationally recognized subject matter experts join company to advise clients, inform strategy and support delivery of technology-enabled solutions

Greater Transparency: Clients Pay the Same as Express Scripts Does for Prescription Drugs

Biocept, Inc. announces that President and CEO Michael W. Nall will present a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth Conference on October 30, 2018 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). The conference is being held in Jupiter, Fla.

Wize Pharma (“Wize Pharma” or the “Company”) (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has entered into a securities purchase agreement with a group of investors, which will result in gross proceeds to Wize Pharma of approximately $4.45 million, before deducting placement agent fees and estimated offering expenses.

Divurgent announced today the appointment of Gary Germaine as Vice President, Client Services. As part of the Client Services team, Gary will be responsible for the continued expansion of Divurgent’s clients, projects, and programs across the Central United States.

DryEyeAccess.com, a subscription-based education website that helps ophthalmology and optometry practices understand how to identify, diagnose, and treat patients with Dry Eye Disease, is now available.

CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company’s common stock during the past 3 months.